Table 8.1
Effects still being confirmed more clinical trials needed Taken together, the studies published so far suggest that GLP-1 anti-obesity drugs may offer positive potential beyond weight loss, including blood sugar control, fatty liver improvement, reduced alcohol use, better mental health, and improved male fertility
Disclaimer : This content is intended for informational purposes only and does not constitute medical advice
Eli Lilly invested $4 billion in expanding its manufacturing facilities in 2024 and 2025, partly in anticipation of retatrutide demand
The world now demands compliance, reliability, and deep design innovation and India must rise to that challenge." Hari Kiran Chereddi, MD & CEO, HRV Pharma and NHG Pharma Global Health Impact and Public Health Imperative The significance of this opportunity extends beyond commercial considerations